This HTML5 document contains 193 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q104060420
rdf:type
wikibase:Item
schema:description
videnskabelig artikel udgivet december 2020 2020年学术文章 2020年学术文章 2020 nî lūn-bûn wissenschaftlicher Artikel 2020年學術文章 artikulong pang-agham научни чланак vedecký článok vitskapeleg artikkel სამეცნიერო სტატია научна статия 2020年学术文章 2020年學術文章 artigo científico articol științific scientific article published in December 2020 บทความทางวิทยาศาสตร์ vitenskapelig artikkel 2020년 논문 tudományos cikk 2020年の論文 vědecký článek teaduslik artikkel artigo científico article científic 2020年學術文章 artículu científicu 2020年學術文章 artikull shkencor scientific article published on 01 December 2020 article scientific مقالة علمية نشرت في ديسمبر 2020 article scientifique vetenskaplig artikel наукова стаття, опублікована в грудні 2020 2020年学术文章 научни чланак מאמר מדעי 2020年學術文章 artigo científico scienca artikolo scientific article published in December 2020 ডিসেম্বর ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ naučni članak bilimsel makale научная статья 2020年学术文章 επιστημονικό άρθρο artikel ilmiah wetenschappelijk artikel bài báo khoa học 2020年学术文章 artículo científico publicado en 2020 articolo scientifico 2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 1ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް artykuł naukowy tieteellinen artikkeli мақолаи илмӣ
p:P577
wds:Q104060420-EAB73A79-D4C2-4A49-89D7-08EF39D1291A
wdt:P577
2020-12-01T00:00:00Z
p:P2860
wds:Q104060420-EB02F771-F783-4397-A677-D10CD87D2110 wds:Q104060420-F1854B94-0F51-48BF-A6C8-1CB973FE9D41 wds:Q104060420-F576080F-2ABF-4B98-9E0A-2D8EB12B4A31 wds:Q104060420-C51CDD2E-0632-4FD7-A3B4-E44BA0B5E3AE wds:Q104060420-C9106F02-20DC-4AE8-8D23-30B483A92495 wds:Q104060420-CDAB7CCA-EFF6-4332-B89B-DC755FDDF024 wds:Q104060420-D8092488-80BA-40A5-A946-7D02C8AC6EE3 wds:Q104060420-B01B3D04-3867-4FB4-84F7-9D02771B1FEC wds:Q104060420-BF1C6759-ACDE-4966-A8A8-7B90E2CB45DE wds:Q104060420-C315E0FD-6D62-4C80-874C-B35C250F7BB5 wds:Q104060420-C43A14DB-3E61-4EF6-854E-D8F8063E8692 wds:Q104060420-803A8106-15FD-4E14-8031-F324D32746AB wds:Q104060420-8A27E01C-8875-4BEF-915E-880562C71067 wds:Q104060420-995F5BBB-75AB-4D81-B6D5-1AB8EDEB9C42 wds:Q104060420-555A3EEA-7484-489F-B80A-724203B04CCF wds:Q104060420-56C3C671-BB27-45DA-8799-5EDBDDB6A225 wds:Q104060420-575A8516-6E92-435B-A4A9-FE4FF45D76D5 wds:Q104060420-6C526CE8-5CF6-4D02-8749-406BED32C224 wds:Q104060420-4A4B0E33-B70A-49E1-BCF4-E8139698143C wds:Q104060420-51138F14-4C3C-48DF-B76F-435ED19369A7 wds:Q104060420-528CC4B2-C66B-459A-8938-86426C6B3C4F wds:Q104060420-2E1CD722-DCCF-4176-BDE1-2757F22F2FE1 wds:Q104060420-33E2E458-0843-48EB-96BD-A3C3EDD3802A wds:Q104060420-3EDC1FE1-FA47-43BD-AB23-DBC3B4E65C98 wds:Q104060420-404E5CED-8462-4CC0-A3AD-D6A583ABE800 wds:Q104060420-020E6DC6-EB55-444D-B63C-42F37B89233F wds:Q104060420-21D6DC0E-20E6-49AB-A4AF-5A2FECDC1E6B
wdt:P2860
wd:Q34547180 wd:Q90342379 wd:Q90916316 wd:Q33186765 wd:Q37329406 wd:Q42473747 wd:Q37173548 wd:Q41616118 wd:Q90630067 wd:Q24685406 wd:Q51792057 wd:Q38549680 wd:Q36087199 wd:Q46270437 wd:Q40160226 wd:Q82576832 wd:Q26783551 wd:Q35856121 wd:Q47799946 wd:Q92635182 wd:Q44615057 wd:Q92042963 wd:Q34334817 wd:Q52591068 wd:Q57291210 wd:Q83135082 wd:Q80244014
p:P2093
wds:Q104060420-FE18ECF3-4F41-4763-9222-878371AD7136 wds:Q104060420-E7E92DD6-6539-4B1A-B413-E13D508B9883 wds:Q104060420-D8DC1A13-F849-4610-A972-90065CE10AC0 wds:Q104060420-21F90F23-9BEB-48C2-B0A9-C556FCEE6514 wds:Q104060420-2DC00E2C-E100-48BF-BD67-EA7726814803 wds:Q104060420-1DC7D641-8A05-4BE7-BD58-13C7E2AFC4C3 wds:Q104060420-042F1B45-527C-4873-8484-845713E1DDF3 wds:Q104060420-70E2841A-3628-4F01-B87F-876BC2A622D5 wds:Q104060420-62D6DD25-B85C-4818-A41E-641FB3737ED5 wds:Q104060420-55EA0DCC-6780-441B-96BC-C3847D24F8CE wds:Q104060420-52F577AE-6567-4526-81F0-26E8DB55D16F wds:Q104060420-4F374855-4730-46D0-8729-8B5D6DE8835B wds:Q104060420-407C7981-B88D-4B1C-AAED-0C4F66054B74 wds:Q104060420-444BDBDF-80B9-4804-8125-DDE7FA0CC9B3 wds:Q104060420-B442E38E-3A2A-47EB-9F10-103FA750FF63 wds:Q104060420-AB3E0B6A-8CCD-4228-A570-BD423436FD2D wds:Q104060420-AD0A1860-0114-42D7-AB0E-48117CF83AAC wds:Q104060420-8DE9F0DC-53D9-444C-B9F2-320307F2AB1F wds:Q104060420-9541FEDF-5B47-46E4-B99B-8332555FA534 wds:Q104060420-8B079362-1C7E-44A7-B039-6227A68F295F
wdt:P2093
Devansu Tewari John K Chan Minal A Barve Ernest Bognar Rodney P Rocconi Jonathan Oh David Shanahan Justin N Bottsford-Miller Staci Horvath Sharad A Ghamande Peter C Morris Erin E Stevens Gladice Wallraven Min Tang Luisa Manning Robert L Coleman Laura Stanbery Elizabeth A Grosen Phylicia Aaron Thomas J Herzog
rdfs:label
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
skos:prefLabel
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
schema:name
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
p:P50
wds:Q104060420-1C9E0254-65A1-46E1-A8CE-967D1A4CE0C7 wds:Q104060420-5D0425A6-E3B6-43A8-9888-E945E660EEE6 wds:Q104060420-74FCF822-0EB0-4809-9AEF-A5ABB0434D54
wdt:P50
wd:Q95970217 wd:Q123915583 wd:Q107013145
p:P1476
wds:Q104060420-B9CE0905-F2B6-46FF-85E7-9757035F2912
wdt:P1476
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
p:P304
wds:Q104060420-34AB86FD-231F-4717-BEA3-6CB723BC98A5
wdt:P304
1661-1672
p:P31
wds:Q104060420-F9EF6CC1-D954-4F19-AC80-3C1B382FB02B
wdt:P31
wd:Q13442814
p:P921
wds:Q104060420-06328E12-3AC3-4C14-A0EC-C77EFC2D3554 wds:Q104060420-45E43ECD-AB1C-4599-9620-8101658AB30B
wdt:P921
wd:Q1427096 wd:Q172341
p:P698
wds:Q104060420-A1E32170-16B6-48A8-9AAD-A111A7726693
wdtn:P698
n11:33271095
wdt:P698
33271095
p:P1433
wds:Q104060420-F9BE31B5-3500-43CD-AED5-FEC36227F609
wdt:P1433
wd:Q13747613
p:P433
wds:Q104060420-045E63ED-D852-4583-8383-212627852592
p:P478
wds:Q104060420-D268B062-6BC3-4F78-86BD-7582C22A70EF
wdt:P433
12
wdt:P478
21
p:P356
wds:Q104060420-3342DEA6-9EFE-4B56-8F18-682476A4980B
wdtn:P356
n12:S1470-2045(20)30533-7
wdt:P356
10.1016/S1470-2045(20)30533-7